Prospective Grant of Exclusive License: Method for Treating Strokes by Inducing Tolerance to E-Selectin, 45058 [E7-15621]

Download as PDF 45058 Federal Register / Vol. 72, No. 154 / Friday, August 10, 2007 / Notices Place: Miyako Hotel, 1625 Post Street, San Francisco, CA 94115. Contact Person: Suzanne L. ForrySchaudies, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6192, MSC 7804, Bethesda, MD 20892, 301–451–0131, forryscs@csr.nih.gov. Name of Committee: Endocrinology, Metabolism, Nutrition and Reproductive Sciences Integrated Review Group, Integrative and Clinical Endocrinology and Reproduction Study Section. Date: September 26–27, 2007. Time: 8 a.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814. Contact Person: Michael Knecht, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6176, MSC 7892, Bethesda, MD 20892, 301–435– 1046, knechtm@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, AcademicIndustrial Partnership for Cancer Imaging. Date: September 28, 2007. Time: 11 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Xiang-Ning Li, MD, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5112, MSC 7854, Bethesda, MD 20892, 301–435– 1744, lixiang@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: August 2, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–3898 Filed 8–9–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Method for Treating Strokes by Inducing Tolerance to E-Selectin National Institutes of Health, Public Health Service, HHS. ACTION: Notice. sroberts on PROD1PC70 with PROPOSALS AGENCY: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is VerDate Aug<31>2005 16:37 Aug 09, 2007 Jkt 211001 contemplating the grant of an exclusive license worldwide to practice the inventions embodied in: U.S. Patent Application Numbers 60/206,693 filed May 24, 2000, 10/296,423 filed November 22, 2002 and corresponding foreign applications entitled ‘‘Method for Preventing Strokes by Inducing Tolerance to E-Selectin’’ and U.S. Patent Application Numbers 60/828,732 filed October 9, 2006 and 60/905,741 filed March 8, 2007 entitled ‘‘Treatment and Prevention of Inflammation’’ to Novavax, Inc., having a place of business in Rockville, Maryland. The patent rights in these inventions have been assigned to the United States of America. The contemplated exclusive license may be limited to the use of E-selectin for the prevention or treatment of stroke. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 9, 2007 will be considered. ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Norbert J. Pontzer, J.D., PhD, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 5502; Facsimile: (301) 402–0220, E-mail: pontzern@mail.nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent application if not yet published. SUPPLEMENTARY INFORMATION: This invention provides methods of treating or preventing brain damage in stroke through administration of E-selectin, an inducible adhesion molecule on endothelial cells. The expression of E-selectin is induced on human endothelium in response to activation by cytokines IL–1 and TNF. E-selectin mediates the adhesion of various leukocytes, including neutrophils, monocytes, eosinophils, natural killer cells, and a subset of T cells to activated endothelium. Activation of vascular endothelial cells by proinflammatory cytokines is believed to be involved in conversion of the luminal surface of endothelium from anticoagulant and anti-inflammatory to procoagulant and pro-inflammatory leading to thrombosis. Segmental vascular activation and thrombosis are involved in the development of strokes. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: August 3, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–15621 Filed 8–9–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel, Musculoskeletal Rehabilitation. Date: August 16, 2007. Time: 2 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Jo Pelham, BA, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4102, MSC 7814, Bethesda, MD 20892, (301) 435–1786, pelhamj@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing E:\FR\FM\10AUN1.SGM 10AUN1

Agencies

[Federal Register Volume 72, Number 154 (Friday, August 10, 2007)]
[Notices]
[Page 45058]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-15621]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Method for Treating 
Strokes by Inducing Tolerance to E-Selectin

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the inventions embodied in: 
U.S. Patent Application Numbers 60/206,693 filed May 24, 2000, 10/
296,423 filed November 22, 2002 and corresponding foreign applications 
entitled ``Method for Preventing Strokes by Inducing Tolerance to E-
Selectin'' and U.S. Patent Application Numbers 60/828,732 filed October 
9, 2006 and 60/905,741 filed March 8, 2007 entitled ``Treatment and 
Prevention of Inflammation'' to Novavax, Inc., having a place of 
business in Rockville, Maryland. The patent rights in these inventions 
have been assigned to the United States of America.
    The contemplated exclusive license may be limited to the use of E-
selectin for the prevention or treatment of stroke.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
October 9, 2007 will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Norbert J. Pontzer, J.D., PhD, Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: (301) 435-5502; Facsimile: (301) 402-0220, E-
mail: pontzern@mail.nih.gov. A signed Confidential Disclosure Agreement 
will be required to receive copies of the patent application if not yet 
published.

SUPPLEMENTARY INFORMATION: This invention provides methods of treating 
or preventing brain damage in stroke through administration of E-
selectin, an inducible adhesion molecule on endothelial cells. The 
expression of E-selectin is induced on human endothelium in response to 
activation by cytokines IL-1 and TNF. E-selectin mediates the adhesion 
of various leukocytes, including neutrophils, monocytes, eosinophils, 
natural killer cells, and a subset of T cells to activated endothelium. 
Activation of vascular endothelial cells by proinflammatory cytokines 
is believed to be involved in conversion of the luminal surface of 
endothelium from anticoagulant and anti-inflammatory to procoagulant 
and pro-inflammatory leading to thrombosis. Segmental vascular 
activation and thrombosis are involved in the development of strokes.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: August 3, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E7-15621 Filed 8-9-07; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.